G

Glenmark Life Sciences Ltd
NSE:GLS

Watchlist Manager
Glenmark Life Sciences Ltd
NSE:GLS
Watchlist
Price: 958.4 INR -3.57%
Market Cap: 117.4B INR
Have any thoughts about
Glenmark Life Sciences Ltd?
Write Note

Glenmark Life Sciences Ltd
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Glenmark Life Sciences Ltd
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
G
Glenmark Life Sciences Ltd
NSE:GLS
Total Receivables
â‚ą9.3B
CAGR 3-Years
9%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Total Receivables
â‚ą84.4B
CAGR 3-Years
7%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Total Receivables
â‚ą55.9B
CAGR 3-Years
17%
CAGR 5-Years
7%
CAGR 10-Years
9%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Total Receivables
â‚ą129.9B
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
10%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Total Receivables
â‚ą17.9B
CAGR 3-Years
5%
CAGR 5-Years
3%
CAGR 10-Years
3%
M
Mankind Pharma Ltd
NSE:MANKIND
Total Receivables
â‚ą9.4B
CAGR 3-Years
18%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Glenmark Life Sciences Ltd
Glance View

Market Cap
117.4B INR
Industry
Pharmaceuticals

Glenmark Life Sciences Ltd., a spin-off from the parent company Glenmark Pharmaceuticals, has carved out its niche in the competitive world of active pharmaceutical ingredients (APIs). This Mumbai-based entity emerged as an independent public company, growing its presence in both the domestic and international markets. Glenmark Life Sciences strategically focuses on the manufacture and supply of high-quality APIs used across a diverse range of therapeutic areas including cardiovascular, central nervous system disorders, diabetes, pain management, and oncology. By maintaining a robust portfolio of over 120 APIs, the company ensures its penetration in the growing pharmaceutical sector, which increasingly demands reliable and efficient raw materials for drug production. Through its four state-of-the-art manufacturing facilities, Glenmark Life Sciences capitalizes on its well-established research and development capabilities to enhance its manufacturing processes and expand its product range. The company's business model is meticulously designed around long-term relationships with major pharmaceutical players, fostering partnerships that drive consistent revenue streams. By leveraging cost-effective manufacturing practices and an expansive distribution network across major pharmaceutical markets, Glenmark Life Sciences not only optimizes its production capabilities but also ensures timely delivery and high-quality standards. The company's success rests on its ability to balance operational efficiency with strategic expansion into high-growth markets, reinforcing its reputation as a reliable API supplier in the global pharmaceutical industry.

GLS Intrinsic Value
729.79 INR
Overvaluation 24%
Intrinsic Value
Price
G

See Also

What is Glenmark Life Sciences Ltd's Total Receivables?
Total Receivables
9.3B INR

Based on the financial report for Mar 31, 2024, Glenmark Life Sciences Ltd's Total Receivables amounts to 9.3B INR.

What is Glenmark Life Sciences Ltd's Total Receivables growth rate?
Total Receivables CAGR 5Y
12%

Over the last year, the Total Receivables growth was 1%. The average annual Total Receivables growth rates for Glenmark Life Sciences Ltd have been 9% over the past three years , 12% over the past five years .

Back to Top